Effectiveness and Safety of Droperidol Use in the VA Greater Los Angeles Healthcare System Emergency Department.

Emily Minoda, Shogo Kono, My-Phuong Pham, Hemang Acharya, Jonathan Balakumar
{"title":"Effectiveness and Safety of Droperidol Use in the VA Greater Los Angeles Healthcare System Emergency Department.","authors":"Emily Minoda, Shogo Kono, My-Phuong Pham, Hemang Acharya, Jonathan Balakumar","doi":"10.12788/fp.0699","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Droperidol, a butyrophenone antipsychotic, is used for postoperative nausea and vomiting and as a sedative, anxiolytic, and analgesic. Concerns about potential QTc (corrected QT interval) prolongation led the US Food and Drug Administration (FDA) to issue a boxed warning and halt manufacturing. However, recent studies have supported droperidol's safety and it was reintroduced in 2019. Given the limited available options for managing acute agitation at the Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS), there has been interest in re-evaluating the risks associated with droperidol use for sedation, anxiolysis, analgesia, and as an antiemetic.</p><p><strong>Methods: </strong>This retrospective chart review examined patients who received droperidol in the VAGLAHS emergency department (ED) from February 2021 to April 2023. The primary outcome was all-cause mortality after droperidol administration within 24 hours. Secondary outcomes included the efficacy of droperidol, incidence of QT prolongation, incidence of extrapyramidal symptoms (EPS) such as akathisia, dystonia, parkinsonism or tardive dyskinesia, and incidence of respiratory depression.</p><p><strong>Results: </strong>Of 207 patients receiving droperidol, 38 (18.4%) were adults aged ≥ 65 years. Droperidol was used for acute agitation in 183 patients (88.4%) and as an antiemetic in 24 (11.6%) patients. No deaths were observed following droperidol administration in a 24-hour period. The need for rescue medication occurred in 15 patients (7.3%). EPS such as tardive dyskinesia and dystonia occurred in 2 (1.0%) patients. No arrhythmias or respiratory depression were observed within 24 hours of administration. No clinically relevant QTc prolongation was observed.</p><p><strong>Conclusions: </strong>No fatalities were seen among patients who received droperidol in the VAGLAHS ED. Despite the boxed warning issued by the FDA, these findings suggest droperidol is safe and effective in managing agitation and as an antiemetic.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"43 5","pages":"180-185"},"PeriodicalIF":0.0000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13557126/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12788/fp.0699","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Droperidol, a butyrophenone antipsychotic, is used for postoperative nausea and vomiting and as a sedative, anxiolytic, and analgesic. Concerns about potential QTc (corrected QT interval) prolongation led the US Food and Drug Administration (FDA) to issue a boxed warning and halt manufacturing. However, recent studies have supported droperidol's safety and it was reintroduced in 2019. Given the limited available options for managing acute agitation at the Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS), there has been interest in re-evaluating the risks associated with droperidol use for sedation, anxiolysis, analgesia, and as an antiemetic.

Methods: This retrospective chart review examined patients who received droperidol in the VAGLAHS emergency department (ED) from February 2021 to April 2023. The primary outcome was all-cause mortality after droperidol administration within 24 hours. Secondary outcomes included the efficacy of droperidol, incidence of QT prolongation, incidence of extrapyramidal symptoms (EPS) such as akathisia, dystonia, parkinsonism or tardive dyskinesia, and incidence of respiratory depression.

Results: Of 207 patients receiving droperidol, 38 (18.4%) were adults aged ≥ 65 years. Droperidol was used for acute agitation in 183 patients (88.4%) and as an antiemetic in 24 (11.6%) patients. No deaths were observed following droperidol administration in a 24-hour period. The need for rescue medication occurred in 15 patients (7.3%). EPS such as tardive dyskinesia and dystonia occurred in 2 (1.0%) patients. No arrhythmias or respiratory depression were observed within 24 hours of administration. No clinically relevant QTc prolongation was observed.

Conclusions: No fatalities were seen among patients who received droperidol in the VAGLAHS ED. Despite the boxed warning issued by the FDA, these findings suggest droperidol is safe and effective in managing agitation and as an antiemetic.

在VA大洛杉矶医疗保健系统急诊科使用氟哌啶醇的有效性和安全性。
背景:氟哌啶醇是一种丁苯酮类抗精神病药,用于治疗术后恶心和呕吐,并作为镇静、抗焦虑和镇痛药。由于担心潜在的QTc(校正QT间期)延长,美国食品和药物管理局(FDA)发布了黑框警告并停止生产。然而,最近的研究支持了哌啶醇的安全性,并于2019年重新引入。鉴于退伍军人事务大洛杉矶医疗保健系统(VAGLAHS)管理急性躁动的可用选择有限,人们有兴趣重新评估哌啶醇用于镇静、抗焦虑、镇痛和止吐的风险。方法:本回顾性图表回顾了2021年2月至2023年4月在VAGLAHS急诊科(ED)接受氟哌啶醇治疗的患者。主要终点是氟哌啶醇给药后24小时内的全因死亡率。次要结局包括哌啶醇的疗效、QT间期延长的发生率、锥体外系症状(EPS)的发生率,如无运动障碍、肌张力障碍、帕金森病或迟发性运动障碍,以及呼吸抑制的发生率。结果:207例接受氟哌啶醇治疗的患者中,38例(18.4%)为年龄≥65岁的成年人。183例(88.4%)患者使用氟哌啶醇治疗急性躁动,24例(11.6%)患者使用止吐剂。给予氟哌啶醇24小时内未观察到死亡。15例(7.3%)患者需要抢救用药。2例(1.0%)患者出现迟发性运动障碍和肌张力障碍等EPS。给药24小时内未见心律失常或呼吸抑制。未观察到与临床相关的QTc延长。结论:在VAGLAHS ED中接受氟哌啶醇治疗的患者中未发现死亡病例。尽管FDA发布了黑框警告,但这些发现表明氟哌啶醇在控制躁动和止吐方面是安全有效的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书